How is the post monoclonal antibodies (mAb) world going to develop in the future of biologics?

  As the pharma industry moves into the future of biologics production what challenges will they be facing? The field of biologics is currently on the brink of a new era of high tech drugs. These new drugs have been engineered to be more efficacious than typical mAbs by having a more targeted structure (i.e. antibody drug conjugates). Recently Amgen …

Download: Predicting quality and reliability: the implications of these factors on the selection of candidates for development

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Steffen Hartmann, Global Head Developability Assessment, Integrated …

Download: Affinity issues of ADCs

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Richard Schasfoort, Chief Scientific Officer, Ibis Technologies, who delivered …

Download: From bispecifics to ADCs: developing Fcab drug conjugates

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Robert Rowlands, Scientist, F-star, who delivered the presentation ‘From …

Download: Overcoming manufacturing challenges and streamlining the development of ADCs

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Bo Kara, Director of Science and Technology, Fujifilm Diosynth …

Download: Site Specific ADC generation using SMARTagTM technology

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr David Rabuka, CSO, Redwood Bioscience, who delivered the presentation …

Download: State of the art analytical methods for antibodies, ADCs and bispecifics characterization

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Alain Beck (Senior Director, Antibody …

Download: Interviews with leaders in the antibody sector – the future of R&D in the antibody, ADC and bispecific space

There is undoubtedly a great deal of research going on within the antibody space, a significant number of therapeutics in the clinic and a lot of upcoming developments to watch out for. At the recent European Antibody Congress 2013, we took some time out to conduct some interviews with key members of the speaker faculty (you can view the full …